Investing in the Pharma sector during these pandemic times is not a bad idea. The pharma industry is at the forefront of the battle against COVID-19 and has responded to this global challenge by ensuring the availability of medicines despite supply chain disruptions, Sun Pharmaceutical Industries Chairman Israel Makov said on Thursday, Aug 27, 2020. Clinical trials are being conducted to test the effectiveness of many existing medicines in treating symptoms of COVID-19, he added while addressing the annual general meeting (AGM) of the company. Some of the global pharmaceutical companies, as well as few Indian firms, have also initiated clinical trials for the development of a COVID-19 vaccine, Makov said. The company is also leveraging IT technology tools to ensure business continuity and to facilitate work-from-home for many employees, Makov said.
The healthcare index hit a record high on Friday led by a rally in sector majors Lupin, Dr Reddy’s Laboratories and Cipla on the back of positive news flow. The sector will remain a market favourite due to earnings visibility, which does not exist for most sectors currently because of the pandemic. Analysts said there is potential for earnings to double in the next five years. The BSE Healthcare index surged 3.5% to 20,404.76; Natco Pharma was the top gainer with a 14% jump. Dr Reddy’s was the second-best performer, ending up 10% at 5,326.70 after scaling an all-time high during the day as the company settled patent litigation for Revlimid with Celgene. This is a boost for the company as Revlimid generic cash flows should be significant for the company at over $700 million, according to analysts.
Lupin’s shares jumped 4.6% and those of Cipla gained over 7% after Perrigo announced a voluntary recall of its albuterol sulphate inhalation aerosols in the US on concerns that some units may not dispense properly due to clogging issues. Lupin and Cipla, which are competitors of Perrigo in the $850 million-$900 million US albuterol sulfate market, could potentially get a 4-6% boost in earnings per share due to this opportunity, according to foreign brokerage Macquarie. The rally in pharma stocks brought the total gain in BSE Healthcare to 86.4%, from its 2020 low of 10,947.99 to a close of 20,404.76 on Friday. The Sensex, which hit a 2020 low of 25,638.9 on March 24, has gained 51% since then to close at 38,845.82 on Friday, Sep 19, 2020. From March 24, when the benchmark hit a 2020 low, pharma stocks have surged as much as 516%. Aarti Drugs has taken the lead among pharma stocks followed by IOL Chemicals, Marksans Pharma, Laurus Labs, Neuland Laboratories, Jubilant Life Sciences and Aurobindo Pharma, which gained 154-435%.
Now I come to your question. Invex searches for and carefully selects assets with high investment potential and stable long-term returns. Our platform allows you to collectively invest in pharmaceutical companies and medical technology start-up’s that were previously only available to professional market players. This format allows you to divide the number of attachments between participants. At the same time, the size of our investment is from 300 thousand to several million. The security level remains high, and the costs associated with selecting and verifying an asset are borne by us. Invex takes all the work with brokers, utilities, and government agencies, which removes all the risks associated with the settlement of conflicts within the object from the investor. Thus, the investor only must choose a tariff, choose the amount to invest, sign a contract and receive payments. Company is located in UNITED KINGDOM.
Jurgen Schwartz, Founder and President of Invex says, “Our goal is the success of our clients and the development of the financial sector in all countries where the brand is represented. This is why we keep our services up to date and introduce innovative products.
“The reason for the creation of our holding was the existing problem of the modern market of investments in the medical sphere: investments require large one-time expenses, and the selection and management of assets takes a long time. In addition, this type of investment requires extensive knowledge in this area, which is possessed by a rather narrow circle of the population.
Moreover, the growth that was observed in the pharmaceutical market over the last decade opens endless opportunities for investors all over the world.”
The answer to your question is yes, the company does exist and I do believe you must gather more information about the company by visiting their Facebook account: https://www.facebook.com/invexlab/about/?ref=page_internal
Besides if you do have any questions give me a call: https://clarity.fm/joy-brotonath
